;PMID: 9603197 ;source_file_2857.mrg ;Release 0.9 of PennBioIE ;Funded by NSF ITR EIA-0205448 ;0)section:[e:0..37] = [t:0..37] ;1)sentence:[e:43..207] = [t:43..207] ;2)section:[e:211..273] = [t:211..273] ;3)section:[e:277..349] = [t:277..349] ;4)sentence:[e:353..606] = [t:353..606] ;5)sentence:[e:607..740] = [t:607..740] ;6)sentence:[e:742..878] = [t:742..878] ;7)sentence:[e:879..1117] = [t:879..1117] ;8)sentence:[e:1118..1314] = [t:1118..1314] ;9)section:[e:1318..1362] = [t:1318..1362] ;section 0 Span:0..37 ;J Neurochem. 1998 Jun;70(6):2327-35. (SEC (FRAG (NNP:[0..1] J) (NNP:[2..11] Neurochem) (.:[11..12] .) (CD:[14..18] 1998) (.:[19..25] Jun;70) (-LRB-:[25..26] -LRB-) (CD:[26..27] 6) (-RRB-:[27..28] -RRB-) (::[28..29] :) (CD:[29..33] 2327) (CD:[33..36] -35) (.:[36..37] .))) ;sentence 1 Span:43..207 ;Effects of a peptide analogue of the amphiphilic domain of the common ;neurotrophin receptor on nerve growth factor-mediated motility of human ;neuroblastoma cells. ;[114..135]:gene-protein:"neurotrophin receptor" ;[139..158]:gene-protein:"nerve growth factor" ;[187..200]:malignancy-type:"neuroblastoma" (SENT (NP-HLN (NP (NNS:[43..50] Effects)) (PP (IN:[51..53] of) (NP (NP (DT:[54..55] a) (NN:[56..63] peptide) (NN:[64..72] analogue)) (PP (IN:[73..75] of) (NP (NP (DT:[76..79] the) (JJ:[80..91] amphiphilic) (NN:[92..98] domain)) (PP (IN:[99..101] of) (NP (DT:[102..105] the) (JJ:[106..112] common) (NN:[114..126] neurotrophin) (NN:[127..135] receptor))))))) (PP (IN:[136..138] on) (NP (NP (ADJP (NN:[139..144] nerve) (NN:[145..151] growth) (NN:[152..158] factor) (HYPH:[158..159] -) (VBN:[159..167] mediated)) (NN:[168..176] motility)) (PP (IN:[177..179] of) (NP (JJ:[180..185] human) (NN:[187..200] neuroblastoma) (NNS:[201..206] cells))))) (.:[206..207] .))) ;section 2 Span:211..273 ;Wang W, Dostaler SM, Lawrence G, Ross GM, Riopelle RJ, Dow KE. (SEC (FRAG (NNP:[211..215] Wang) (NNP:[216..217] W) (,:[217..218] ,) (NNP:[219..227] Dostaler) (NNP:[228..230] SM) (,:[230..231] ,) (NNP:[232..240] Lawrence) (NNP:[241..242] G) (,:[242..243] ,) (NNP:[244..248] Ross) (NNP:[249..251] GM) (,:[251..252] ,) (NNP:[253..261] Riopelle) (NNP:[262..264] RJ) (,:[264..265] ,) (NNP:[266..269] Dow) (NNP:[270..273] KE.))) ;section 3 Span:277..349 ;Department of Pediatrics, Queen's University, Kingston, Ontario, Canada. (SEC (FRAG (NNP:[277..287] Department) (IN:[288..290] of) (NNP:[291..301] Pediatrics) (,:[301..302] ,) (NNP:[303..308] Queen) (POS:[308..310] 's) (NNP:[311..321] University) (,:[321..322] ,) (NNP:[323..331] Kingston) (,:[331..332] ,) (NNP:[333..340] Ontario) (,:[340..341] ,) (NNP:[342..348] Canada) (.:[348..349] .))) ;sentence 4 Span:353..606 ;Exposure of human neuroblastoma cells (IMR-32) to a peptide mimic of the ;cytoplasmic amphiphilic domain of the common neurotrophin receptor (p75NTR ;367-379) resulted in enhanced nerve growth factor (NGF)-mediated inhibition ;of cell invasion in vitro. ;[371..384]:malignancy-type:"neuroblastoma" ;[472..493]:gene-protein:"neurotrophin receptor" ;[495..501]:gene-protein:"p75NTR" ;[533..552]:gene-protein:"nerve growth factor" ;[554..557]:gene-protein:"NGF" (SENT (S (NP-SBJ (NP (NN:[353..361] Exposure)) (PP (IN:[362..364] of) (NP (JJ:[365..370] human) (NN:[371..384] neuroblastoma) (NNS:[385..390] cells))) (PRN (-LRB-:[391..392] -LRB-) (NP (NN:[392..398] IMR-32)) (-RRB-:[398..399] -RRB-)) (PP (TO:[400..402] to) (NP (NP (DT:[403..404] a) (NN:[405..412] peptide) (NN:[413..418] mimic)) (PP (IN:[419..421] of) (NP (NP (DT:[422..425] the) (JJ:[427..438] cytoplasmic) (JJ:[439..450] amphiphilic) (NN:[451..457] domain)) (PP (IN:[458..460] of) (NP (NP (DT:[461..464] the) (JJ:[465..471] common) (NN:[472..484] neurotrophin) (NN:[485..493] receptor)) (NP (-LRB-:[494..495] -LRB-) (NN:[495..501] p75NTR) (CD:[503..506] 367) (HYPH:[506..507] -) (CD:[507..510] 379) (-RRB-:[510..511] -RRB-))))))))) (VP (VBD:[512..520] resulted) (PP-CLR (IN:[521..523] in) (NP (NP (VBN:[524..532] enhanced) (ADJP (NML (NML (NN:[533..538] nerve) (NN:[539..545] growth) (NN:[546..552] factor)) (NML (-LRB-:[553..554] -LRB-) (NN:[554..557] NGF) (-RRB-:[557..558] -RRB-))) (HYPH:[558..559] -) (VBN:[559..567] mediated)) (NN:[568..578] inhibition)) (PP (IN:[579..581] of) (NP (NN:[583..587] cell) (NN:[588..596] invasion))) (ADJP (FW:[597..599] in) (FW:[600..605] vitro))))) (.:[605..606] .))) ;sentence 5 Span:607..740 ;The peptide also enhanced NGF-mediated neurite extension and GAP-43 gene ;expression but had no effect on NGF-mediated cell survival. ;[633..636]:gene-protein:"NGF" ;[669..675]:gene-rna:"GAP-43" ;[713..716]:gene-protein:"NGF" (SENT (S (NP-SBJ (DT:[607..610] The) (NN:[611..618] peptide)) (ADVP (RB:[619..623] also)) (VP (VP (VBD:[624..632] enhanced) (NP (NP (ADJP (NN:[633..636] NGF) (HYPH:[636..637] -) (VBN:[637..645] mediated)) (NN:[646..653] neurite) (NN:[654..663] extension)) (CC:[665..668] and) (NP (NN:[669..675] GAP-43) (NN:[676..680] gene) (NN:[681..691] expression)))) (CC:[692..695] but) (VP (VBD:[696..699] had) (NP (NP (DT:[700..702] no) (NN:[703..709] effect)) (PP (IN:[710..712] on) (NP (ADJP (NN:[713..716] NGF) (HYPH:[716..717] -) (VBN:[717..725] mediated)) (NN:[726..730] cell) (NN:[731..739] survival)))))) (.:[739..740] .))) ;sentence 6 Span:742..878 ;These latter functional effects mimicked influences on NGF-mediated neurite ;growth in other trkA-positive cells as reported previously. ;[797..800]:gene-protein:"NGF" ;[835..839]:gene-generic:"trkA" (SENT (S (NP-SBJ (DT:[742..747] These) (JJ:[748..754] latter) (JJ:[755..765] functional) (NNS:[766..773] effects)) (VP (VBD:[774..782] mimicked) (NP (NNS:[783..793] influences) (PP (IN:[794..796] on) (NP (ADJP (NN:[797..800] NGF) (HYPH:[800..801] -) (VBN:[801..809] mediated)) (NN:[810..817] neurite) (NN:[819..825] growth)))) (PP (IN:[826..828] in) (NP (JJ:[829..834] other) (ADJP (NN:[835..839] trkA) (HYPH:[839..840] -) (JJ:[840..848] positive)) (NNS:[849..854] cells))) (SBAR (IN:[855..857] as) (S (NP-SBJ-1 (-NONE-:[857..857] *)) (VP (VBN:[858..866] reported) (NP-1 (-NONE-:[866..866] *)) (ADVP-TMP (RB:[867..877] previously)))))) (.:[877..878] .))) ;sentence 7 Span:879..1117 ;NGF-dependent trkA phosphorylation was significantly enhanced by the ;presence of the peptide, whereas high-affinity binding of 125I-NGF, both NGF ;receptors mRNA and protein expression, and trkA dimer/monomer ratios were ;not influenced. ;[879..882]:gene-protein:"NGF" ;[893..897]:gene-generic:"trkA" ;[1013..1016]:gene-protein:"NGF" ;[1023..1036]:gene-protein:"NGF receptors" ;[1023..1036]:gene-rna:"NGF receptors" ;[1071..1075]:gene-protein:"trkA" (SENT (S (NP-SBJ-1 (ADJP (NN:[879..882] NGF) (HYPH:[882..883] -) (JJ:[883..892] dependent)) (NN:[893..897] trkA) (NN:[899..914] phosphorylation)) (VP (VBD:[915..918] was) (ADVP (RB:[919..932] significantly)) (VP (VBN:[933..941] enhanced) (NP-1 (-NONE-:[941..941] *)) (PP (IN:[942..944] by) (NP (NP (DT:[945..948] the) (NN:[949..957] presence)) (PP (IN:[958..960] of) (NP (DT:[961..964] the) (NN:[965..972] peptide))))) (,:[972..973] ,) (SBAR-ADV (IN:[975..982] whereas) (S (NP-SBJ-4 (NP (NP (ADJP (JJ:[983..987] high) (HYPH:[987..988] -) (NN:[988..996] affinity)) (NN:[997..1004] binding)) (PP (IN:[1005..1007] of) (NP (NP (NN:[1008..1013] 125I-) (NN:[1013..1016] NGF)) (,:[1016..1017] ,) (NP (CC:[1018..1022] both) (NP (NN:[1023..1026] NGF) (NNS:[1027..1036] receptors) (NN:[1037..1041] mRNA)) (CC:[1042..1045] and) (NP (NN:[1046..1053] protein) (NN:[1055..1065] expression))) (,:[1065..1066] ,)))) (CC:[1067..1070] and) (NP (NP (NML-2 (NN:[1071..1075] trkA)) (NN:[1076..1081] dimer) (NML-3 (-NONE-:[1081..1081] *P*))) (SYM:[1081..1082] /) (NP (NML-2 (-NONE-:[1082..1082] *P*)) (NN:[1082..1089] monomer) (NML-3 (NNS:[1090..1096] ratios))))) (VP (VBD:[1097..1101] were) (RB:[1102..1105] not) (VP (VBN:[1106..1116] influenced) (NP-4 (-NONE-:[1116..1116] *)))))))) (.:[1116..1117] .))) ;sentence 8 Span:1118..1314 ;The studies suggest that ligand-mediated trkA activation has differential ;effects on cell motility phenomena and that the amphiphilic domain of p75NTR ;has a role in this differential signaling. ;[1160..1164]:gene-generic:"trkA" ;[1264..1270]:gene-protein:"p75NTR" (SENT (S (NP-SBJ (DT:[1118..1121] The) (NNS:[1122..1129] studies)) (VP (VBP:[1131..1138] suggest) (SBAR (SBAR (IN:[1139..1143] that) (S (NP-SBJ (ADJP (NN:[1144..1150] ligand) (HYPH:[1150..1151] -) (VBN:[1151..1159] mediated)) (NN:[1160..1164] trkA) (NN:[1165..1175] activation)) (VP (VBZ:[1176..1179] has) (NP (NP (JJ:[1180..1192] differential) (NNS:[1193..1200] effects)) (PP (IN:[1201..1203] on) (NP (NN:[1204..1208] cell) (NN:[1210..1218] motility) (NNS:[1219..1228] phenomena))))))) (CC:[1229..1232] and) (SBAR (IN:[1233..1237] that) (S (NP-SBJ (NP (DT:[1238..1241] the) (JJ:[1242..1253] amphiphilic) (NN:[1254..1260] domain)) (PP (IN:[1261..1263] of) (NP (NN:[1264..1270] p75NTR)))) (VP (VBZ:[1271..1274] has) (NP (DT:[1275..1276] a) (NN:[1277..1281] role)) (PP (IN:[1282..1284] in) (NP (DT:[1285..1289] this) (JJ:[1291..1303] differential) (NN:[1304..1313] signaling)))))))) (.:[1313..1314] .))) ;section 9 Span:1318..1362 ;PMID: 9603197 [PubMed - indexed for MEDLINE] (SEC (FRAG (NNP:[1318..1322] PMID) (::[1322..1323] :) (CD:[1324..1331] 9603197) (NN:[1332..1333] -LSB-) (NNP:[1333..1339] PubMed) (::[1340..1341] -) (NN:[1342..1349] indexed) (IN:[1350..1353] for) (NNP:[1354..1362] MEDLINE-RSB-)))